Neuralstem Reports Second Quarter Financial Results and Provides Business and Clinical Update

ROCKVILLE, Md., Aug. 10, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) reported its financial results for the three months and six months period ended June 30, 2011 and provided a business and clinical update.


"The Company reached two U.S. clinical trial milestones and one important international milestone in the second Quarter," said Neuralstem's Chairman and Chief Scientific Officer Karl Johe, PhD. "We completed the first 12 ALS patients' lumbar-area transplantations, and have been approved by the trial's Safety Monitoring Board to proceed to cervical-area injections. Under our approved protocol, this data must also be reviewed by the FDA to proceed to the next step of the trial which will entail cervical-area transplantations in ambulatory ALS patients. This is an important step as we believe that the cervical injections may ultimately help patients with their breathing and swallowing."

"The dosing of healthy volunteers is near completion in our FDA-approved Phase Ia safety trial evaluating NSI-189, our first small molecule compound, for the treatment of major depression. Upon review of the data and approval, we will test the safety and tolerability of escalating doses of daily administration for 28 days in depressed patients in a Phase Ib trial. We hope to start the Ib trial early this fall," continued Dr. Johe. "Internationally, we entered into an agreement for a trial to treat chronic motor disorder from ischemic stroke with BaYi Brain Hospital in Beijing. We believe this trial will commence in early 2012. This will be the first trial where the Company's neural stem cells will be injected directly into the brain."